Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.


Autoria(s): Viard I.; Wehrli P.; Bullani R.; Schneider P.; Holler N.; Salomon D.; Hunziker T.; Saurat J.H.; Tschopp J.; French L.E.
Data(s)

1998

Resumo

Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.

Identificador

http://serval.unil.ch/?id=serval:BIB_4E0C4E1AA94B

isbn:0036-8075 (Print)

pmid:9774279

doi:10.1126/science.282.5388.490

isiid:000076479600059

Idioma(s)

en

Fonte

Science, vol. 282, no. 5388, pp. 490-493

Palavras-Chave #Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Blocking/immunology; Antibodies, Blocking/therapeutic use; Antigens, CD95/immunology; Antigens, CD95/physiology; Apoptosis; Child; Dermis/pathology; Disease Progression; Epidermal Necrolysis, Toxic/pathology; Epidermal Necrolysis, Toxic/therapy; Epidermis/pathology; Fas Ligand Protein; Female; Humans; Immunoglobulins, Intravenous/therapeutic use; Jurkat Cells; Keratinocytes/metabolism; Keratinocytes/pathology; Male; Membrane Glycoproteins/metabolism; Middle Aged; Pilot Projects
Tipo

info:eu-repo/semantics/article

article